NCT01649271 2025-02-11Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.Boehringer IngelheimPhase 1 Completed13 enrolled 11 charts
NCT00950742 2025-02-10Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With HerceptinĀ® in Patients With HER2-positive Advanced Breast Cancer.Boehringer IngelheimPhase 1 Completed18 enrolled 14 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled